IAG933 manufacturers
- IAG933
-
-
2026-08-15
- CAS:2714434-21-4
- Min. Order: 1KG
- Purity: 98
- Supply Ability: 1000 KG
- IAG933
-
- $328.00
-
2026-07-30
- CAS:2714434-21-4
- Purity: 99.31%
- Supply Ability: 10g
|
| Product Name: | IAG933 | | Synonyms: | IAG933;YAP-TEAD-IN-3;4-(5-Chloro-6-fluoro-2-phenyl-2-(pyrrolidin-2-yl)-2,3-dihydrobenzofuran-4-yl)-5-fluoro-6-(2-hydroxyethoxy)-N-methylnicotinamide;3-Pyridinecarboxamide, 4-[(2S)-5-chloro-6-fluoro-2,3-dihydro-2-phenyl-2-(2S)-2-pyrrolidinyl-4-benzofuranyl]-5-fluoro-6-(2-hydroxyethoxy)-N-methyl-, (4S)- | | CAS: | 2714434-21-4 | | MF: | C27H26ClF2N3O4 | | MW: | 529.96 | | EINECS: | | | Product Categories: | | | Mol File: | 2714434-21-4.mol |  |
| | IAG933 Chemical Properties |
| Boiling point | 626.125±55.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.367±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 13.275±0.46(predicted) | | form | Solid | | color | White to off-white | | InChIKey | HUVOYQMXUNTUAI-UHFFFAOYSA-N | | SMILES | ClC1=C(C=C2C(=C1C1=C(C(=NC=C1C(=O)NC)OCCO)F)CC(C1C=CC=CC=1)(C1NCCC1)O2)F |
| | IAG933 Usage And Synthesis |
| Uses | IAG933 (YAP-TEAD-IN-3) is an orally available YAP/TAZ-TEAD inhibitor that has anti-tumor effects and promotes apoptosis. IAG933 YAP-TEAD-IN-3 inhibits Avi-human TEAD4217-434, with an IC50 value of 9 nM[1][2]. | | in vivo | IAG933 (30-240 mg/kg, i.g., once a day, 28 days) shows a dose-dependent anti-tumor effect in mouse xenograft models, promoting cell apoptosis[2].
IAG933 (3-30 mg/kg, i.g., once a day, 2 weeks) causes tumor regression in the MSTO-211H rat xenograft model[2]. | Animal Model: | Mouse MSTO-211H cell-derived xenograft (CDX) model; mouse NCI-H226 cell-derived xenograft (CDX) model[2] | | Dosage: | 30, 60, 120, 240 mg/kg, single dose; 70, 210 mg/kg, once daily, 28 days | | Administration: | i.g. | | Result: | Had a short half-life in mice, inhibiting the transcription of TEAD in the body, promoting apoptosis, and lowering the expression of BCL2L1 and MCL1.
Led to tumor regression and a decrease in Ki67 expression.
|
| Animal Model: | A rat MSTO-211H xenograft model[2] | | Dosage: | 3, 10, 30 mg/kg, once daily, 2 weeks | | Administration: | i.g. | | Result: | Showed the tumor stagnant at 10 mg/kg, and shrank at 30 mg/kg. |
| | IC 50 | YAP/TAZ-TEAD | | References | [1] Bordas V, et al. Preparation of biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors. World Intellectual Property Organization, WO2021186324 A1. 2021-09-23.
[2] Emilie A Chapeau， et al. Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers. Nat Cancer. 2024 Jul;5(7):1102-1120. DOI:10.1038/s43018-024-00754-9 |
| | IAG933 Preparation Products And Raw materials |
|